The Advertising Standards Authority (ASA) has issued a ruling on medical device advertising that clarifies that UK Conformity Assessed (UKCA) marking alone does not constitute sufficient evidence for medical efficacy claims. The ASA determined that clinical trial evidence must predate advertising claims, and customer surveys or app data alone cannot substantiate medical claims. The ruling also established that temporary effects of medical devices must be clearly qualified in advertising. Although the ruling was published after the Digital Markets, Competition and Consumers Act 2024 (DMCCA 2024) came into force, the ASA clarified that the facts occurred before 7 April 2025, and therefore the previous regime applied.